EP1185547A4 - Gene expression modulated in gastrointestinal inflammation - Google Patents

Gene expression modulated in gastrointestinal inflammation

Info

Publication number
EP1185547A4
EP1185547A4 EP00942732A EP00942732A EP1185547A4 EP 1185547 A4 EP1185547 A4 EP 1185547A4 EP 00942732 A EP00942732 A EP 00942732A EP 00942732 A EP00942732 A EP 00942732A EP 1185547 A4 EP1185547 A4 EP 1185547A4
Authority
EP
European Patent Office
Prior art keywords
gene expression
gastrointestinal inflammation
expression modulated
modulated
gastrointestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00942732A
Other languages
German (de)
French (fr)
Other versions
EP1185547A2 (en
Inventor
Joanne Viney
John E Sims
Robert F Dubose
Brian S Hilbush
Karl W Hasel
Robert R Buchner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUROME Inc
Original Assignee
Digital Gene Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Digital Gene Technologies Inc filed Critical Digital Gene Technologies Inc
Publication of EP1185547A2 publication Critical patent/EP1185547A2/en
Publication of EP1185547A4 publication Critical patent/EP1185547A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP00942732A 1999-06-10 2000-06-09 Gene expression modulated in gastrointestinal inflammation Withdrawn EP1185547A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13848799P 1999-06-10 1999-06-10
US138487P 1999-06-10
PCT/US2000/015973 WO2000077166A2 (en) 1999-06-10 2000-06-09 Gene expression modulated in gastrointestinal inflammation

Publications (2)

Publication Number Publication Date
EP1185547A2 EP1185547A2 (en) 2002-03-13
EP1185547A4 true EP1185547A4 (en) 2003-01-02

Family

ID=22482247

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00942732A Withdrawn EP1185547A4 (en) 1999-06-10 2000-06-09 Gene expression modulated in gastrointestinal inflammation

Country Status (7)

Country Link
EP (1) EP1185547A4 (en)
JP (1) JP2004500028A (en)
AU (1) AU5731500A (en)
CA (1) CA2376667A1 (en)
HK (1) HK1045327A1 (en)
MX (1) MXPA01012717A (en)
WO (1) WO2000077166A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002031114A2 (en) * 2000-10-11 2002-04-18 Digital Gene Technologies, Inc. Gene expression modulated in ileitis
DE10101792B4 (en) * 2001-01-17 2004-03-18 Vivotec Biomedical Technologies Gmbh Procedure for the detection of pancreatic carcinoma or chronic pancreatitis and use of antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0879889A2 (en) * 1997-05-19 1998-11-25 Smithkline Beecham Corporation A novel member of the IL-1 family, IL-1 delta

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024513A1 (en) * 1992-05-22 1993-12-09 The Children's Hospital Of Philadelphia Gastrointestinal defensins, cdna sequences and method for the production and use thereof
US5695995A (en) * 1994-05-06 1997-12-09 Fred Hutchinson Cancer Research Center Neurogenic differentiation (neurod) genes
WO1996039419A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Colon specific genes and proteins
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0879889A2 (en) * 1997-05-19 1998-11-25 Smithkline Beecham Corporation A novel member of the IL-1 family, IL-1 delta

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARAI YOSHINORI ET AL: "Involvement of interleukin-1 in the development of ulcerative colitis induced by dextran sulfate sodium in mice.", CYTOKINE, vol. 10, no. 11, November 1998 (1998-11-01), pages 890 - 896, XP002217114, ISSN: 1043-4666 *
DATABASE EMBL [online] 1 January 1997 (1997-01-01), MARRA ET AL., XP002217116, retrieved from EBI Database accession no. AA178128 *
DIELEMAN L A ET AL: "Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines.", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 114, no. 3, December 1998 (1998-12-01), pages 385 - 391, XP002217115, ISSN: 0009-9104 *
See also references of WO0077166A3 *

Also Published As

Publication number Publication date
CA2376667A1 (en) 2000-12-21
JP2004500028A (en) 2004-01-08
WO2000077166A2 (en) 2000-12-21
HK1045327A1 (en) 2002-11-22
MXPA01012717A (en) 2002-07-02
AU5731500A (en) 2001-01-02
WO2000077166A3 (en) 2001-05-17
EP1185547A2 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
AU5805700A (en) Glucoamylase variant
GB9904905D0 (en) Cells
IL128193A0 (en) Rhamnosyl-transferase gene and uses thereof
PL353215A1 (en) Phospholipin gel
HUP0105208A3 (en) Gene therapy-1
IL146332A0 (en) PrP-LIKE GENE
AU2376200A (en) Insulin-synthesis genes
EP1128451A4 (en) Cell
HK1045327A1 (en) Gene expression modulated in gastrointestinal inflammation
AU2057900A (en) Micro-targeted advertising
EP1215284A4 (en) Tsg-like gene
EP1181385A4 (en) Modulation of gene expression in gastrointestinal inflammation
AU5796100A (en) Mucin
AU5706100A (en) Animal defective in uti gene function
GB9928172D0 (en) Modulator
AU1940P (en) Bill Winter Ceratopetalum gummiferum
GB9912543D0 (en) Gene
GB9910522D0 (en) Gene
AUPQ024699A0 (en) Improvements in tunnel kilns
GB9920216D0 (en) Three in one
GB9920335D0 (en) Signs
AUPQ323799A0 (en) Message card
GB9901314D0 (en) The binary display
GB9908683D0 (en) Cells
GB9922006D0 (en) Pedagogy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011217

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20021119

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DA4 Supplementary search report drawn up and despatched (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20030725

17Q First examination report despatched

Effective date: 20031117

19U Interruption of proceedings before grant

Effective date: 20040407

19W Proceedings resumed before grant after interruption of proceedings

Effective date: 20051004

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEUROME, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060403

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1045327

Country of ref document: HK